NYSE · CLX
The Clorox Company
Consumer Defensive · Household & Personal Products
$86.40▼ 2.55% ($2.26)today
As of 4:00 PM ET
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 8.0% a year for 10 years. Our scenarios assume 0.6–4.4%.
Its past 4 years averaged −1.4% a year.
Value per share
Base case
$226.96
Price used $86.40 is 62% below this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
Revenue each value needs
Revenue today $6.7B. The price needs $2.9B by 2036. Base case: $7.3B. At its recent pace: $5.8B. Bear to Bull: $7.1B to $10.3B.
Revenue today $6.7B. The price needs $2.9B by 2036. Base case: $7.3B. At its recent pace: $5.8B. Bear to Bull: $7.1B to $10.3B.
Revenue in 2036
today $6.7B
−$4.4Bless than the Base case
Value per share · Base case
$226.96
Price $86.40
62% below this
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 27.3%
- Discount rate
- 5.9%
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 24.95% over the last year. Revenue declined 5.41% in FY2026 versus FY2025. Operating margin moved from 16.57% to 24.73% (FY2026 versus FY2025). Free cash flow declined 46.78% in FY2026 versus FY2025.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at 24.73%. Revenue declined 5.41% — this read reverses if that trend stabilizes. Free cash flow fell 46.78% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
3
Buy
21
Hold
5
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 2, 2026
Q1 FY27 · EPS est $1.07 · Revenue est $1.9B
Same quarter, year over year
FY26 Full year -28.3%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q4 combined $5.54 vs $7.73 · 1 of 4 quarters up
Q1
Q2
Q3
Q4
FY total
FY27
—
—
—
—
FY26
FY25
FY24
Fiscal year totals
- FY26
- $5.54
- -28.3%
- FY25
- $7.73
- +25.1%
- FY24
- $6.18
- —
Q4 FY26
Reported Aug 3, 2026 · Latest
HoverTap a cell to inspect
Actual
$1.66
Estimate
$1.64
Year over year
-42.2%
Vs prior quarter
+1.2%
Institutional Sentiment
The Clorox Company · CLX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.